4882 Stock Overview A drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Perseus Proteomics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Perseus Proteomics Historical stock prices Current Share Price JP¥571.00 52 Week High JP¥876.00 52 Week Low JP¥291.00 Beta 0.68 1 Month Change -21.78% 3 Month Change 2.33% 1 Year Change 8.14% 3 Year Change 59.94% 5 Year Change n/a Change since IPO -34.06%
Recent News & Updates
Here's Why We're Not Too Worried About Perseus Proteomics' (TSE:4882) Cash Burn Situation Dec 13
Perseus Proteomics Inc. Announces Extension of Investigator-Led Phase I/II Clinical Trial for Aggressive NK-cell Leukemia (ANKL) Dec 12
Perseus Proteomics Inc. Announces Registration of Patent Jointly Filed with Juntendo University Sep 27
Perseus Proteomics Inc. to Report Q2, 2025 Results on Nov 14, 2024 Aug 27
First quarter 2025 earnings released: JP¥15.77 loss per share (vs JP¥35.89 loss in 1Q 2024) Aug 19
Full year 2024 earnings released: JP¥93.65 loss per share (vs JP¥66.84 loss in FY 2023) Jun 25 See more updates
Here's Why We're Not Too Worried About Perseus Proteomics' (TSE:4882) Cash Burn Situation Dec 13
Perseus Proteomics Inc. Announces Extension of Investigator-Led Phase I/II Clinical Trial for Aggressive NK-cell Leukemia (ANKL) Dec 12
Perseus Proteomics Inc. Announces Registration of Patent Jointly Filed with Juntendo University Sep 27
Perseus Proteomics Inc. to Report Q2, 2025 Results on Nov 14, 2024 Aug 27
First quarter 2025 earnings released: JP¥15.77 loss per share (vs JP¥35.89 loss in 1Q 2024) Aug 19
Full year 2024 earnings released: JP¥93.65 loss per share (vs JP¥66.84 loss in FY 2023) Jun 25
Full year 2024 earnings released: JP¥93.65 loss per share (vs JP¥66.84 loss in FY 2023) May 21
Perseus Proteomics Inc., Annual General Meeting, Jun 20, 2024 May 17
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera May 11
New minor risk - Shareholder dilution Apr 27 Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch) Mar 07
Perseus Proteomics Inc. to Report Fiscal Year 2024 Results on May 15, 2024 Mar 02
Third quarter 2024 earnings released Feb 16
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera Feb 02
Perseus Proteomics Inc. to Report Q3, 2024 Results on Feb 14, 2024 Nov 30
Second quarter 2024 earnings released Nov 14
Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV) Oct 21
Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/Reagents Oct 11
Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning Technology Sep 28
Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell Leukemia Sep 23
Perseus Proteomics Inc. to Report Q2, 2024 Results on Nov 13, 2023 Sep 02
First quarter 2024 earnings released: JP¥35.89 loss per share (vs JP¥17.01 loss in 1Q 2023) Aug 16
Perseus Proteomics Inc. to Report Q1, 2024 Results on Aug 14, 2023 Jun 03
Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003 May 30
Full year 2023 earnings released May 13
Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2023 May 13
Third quarter 2023 earnings released: JP¥16.92 loss per share (vs JP¥10.12 loss in 3Q 2022) Feb 15
Perseus Proteomics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 Feb 14
Perseus Proteomics Inc. Announces Extension of Phase I Clinical Trial of PPMX-T003 among Polycythemia Vera Patients Feb 07
Perseus Proteomics Inc. to Report Q3, 2023 Results on Feb 13, 2023 Nov 27
Second quarter 2023 earnings released: JP¥13.86 loss per share (vs JP¥10.12 loss in 2Q 2022) Nov 16
No independent directors Nov 16
Second quarter 2023 earnings released: JP¥13.86 loss per share (vs JP¥10.12 loss in 2Q 2022) Nov 13
Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2023 Nov 12
Perseus Proteomics Inc. to Report Q2, 2023 Results on Nov 11, 2022 Sep 02
Perseus Proteomics Inc. Announces First/Second Patients Dosed in Phase I Clinical Trial Among Polycythemia Vera (Pv) Patients Aug 25
Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2023 Aug 13
Perseus Proteomics Inc. to Report Q1, 2023 Results on Aug 12, 2022 Jun 02
Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2022 May 14
No independent directors Apr 27
Perseus Proteomics Inc. to Report Fiscal Year 2022 Results on May 13, 2022 Apr 08
Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2022 Feb 16
Perseus Proteomics Inc. Announces Initiation of Phase I Clinical Trial in Polycythemia Vera Patients Sep 15 Shareholder Returns 4882 JP Biotechs JP Market 7D -7.0% -2.0% -0.02% 1Y 8.1% 20.2% 14.6%
See full shareholder returns
Return vs Industry: 4882 underperformed the JP Biotechs industry which returned 20.2% over the past year.
Return vs Market: 4882 underperformed the JP Market which returned 14.6% over the past year.
Price Volatility Is 4882's price volatile compared to industry and market? 4882 volatility 4882 Average Weekly Movement 10.3% Biotechs Industry Average Movement 6.8% Market Average Movement 3.6% 10% most volatile stocks in JP Market 7.3% 10% least volatile stocks in JP Market 1.9%
Stable Share Price: 4882's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4882's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate.
Show more Perseus Proteomics Inc. Fundamentals Summary How do Perseus Proteomics's earnings and revenue compare to its market cap? 4882 fundamental statistics Market cap JP¥8.12b Earnings (TTM ) -JP¥966.00m Revenue (TTM ) JP¥109.00m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4882 income statement (TTM ) Revenue JP¥109.00m Cost of Revenue JP¥11.00m Gross Profit JP¥98.00m Other Expenses JP¥1.06b Earnings -JP¥966.00m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -65.53 Gross Margin 89.91% Net Profit Margin -886.24% Debt/Equity Ratio 0%
How did 4882 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/25 12:46 End of Day Share Price 2024/12/25 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Perseus Proteomics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
